Annovis Bio Receives Buy Rating Reaffirmation Amid Mixed Analyst Coverage

Annovis Bio shares received renewed attention from Wall Street this week as Canaccord Genuity Group reaffirmed its bullish stance on the biotechnology company. The investment firm reissued its buy rating on the stock in a research note released Tuesday, signaling continued confidence in the company’s prospects despite recent market volatility. The New York Stock Exchange-listed The post Annovis…